Navigation Links
Stemline Therapeutics Raises $12.5 Million
Date:4/9/2008

Proceeds to advance oncology therapeutics targeting cancer stem cells

NEW YORK, April 9, 2008 /PRNewswire/ -- Stemline Therapeutics, Inc., a clinical stage biopharmaceutical company and a leading developer of oncology compounds directed to cancer stem cell targets, today announced that it has completed a $12.5 million round of financing with healthcare funds managed by Pequot Capital Management, Inc.

Stemline's CEO, Ivan Bergstein, MD, said. "We are very pleased to have consummated this transaction with a fund of this caliber. The capital provides us with significant runway to advance our clinical program, while continuing to build out our pipeline, discovery platform, and comprehensive IP estate. Moreover, this financing allows us to continue to strengthen our leadership position in the rapidly emerging cancer stem cell field."

About Stemline Therapeutics, Inc.

Stemline Therapeutics, Inc. is a clinical stage biotechnology company developing novel oncology compounds directed to cancer stem cell targets. Stemline's lead compound, SL-401, targets the interleukin-3 receptor present on multiple hematological cancers including leukemia blasts and leukemia cancer stem cells. SL-401 has demonstrated single agent anti-tumor activity at tolerable doses in a multi-center Phase I human trial. In addition, Stemline is developing a portfolio of compounds directed at this and other high value cancer stem cell targets of a variety of hematological and solid cancers. Stemline has also built a robust discovery platform called "StemScreen(R)" which the Company has utilized to identify multiple compounds that target and impair cancer stem cells. For more information, please visit the Company's website at http://www.stemline.com.


'/>"/>
SOURCE Stemline Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
2. Amsterdam Molecular Therapeutics Part of Next Biotech Index
3. Sirion Therapeutics Highlights Pivotal Trial Results of Durezol(TM) at the American Society of Cataract and Refractive Surgery Annual Symposium
4. Alba Therapeutics Announces Appointment of Bruce A. Peacock as its Chief Executive Officer
5. Amsterdam Molecular Therapeutics to Appoint George Morstyn to Supervisory Board
6. DiObex Announces Presentation of Scientific Poster at Annual Meeting of American Society for Clinical Pharmacology and Therapeutics
7. ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007
8. Mercury Therapeutics Patents Filed
9. Cell Therapeutics, Inc. Announces Filing of Form 10-K
10. Vicus Therapeutics Announces Participation at 15th International Molecular Medicine Tri-Conference
11. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014  PAREXEL International Corporation (NASDAQ: ... be presenting at the Baird Healthcare Conference in New ... Chief Financial Officer, will be making a presentation on ... on Wednesday, Sept. 3, 2014. A live ... "Investors" section of PAREXEL,s website at www.PAREXEL.com ...
(Date:8/20/2014)... Canada (PRWEB) August 20, 2014 Not ... that E&L studies should be performed late in the ... is known. But current regulatory trends suggest that, like ... on the rise. In recent years, multiple drug sponsors ... packages or address specific questions during phase I/II. It’s ...
(Date:8/20/2014)... the health of your heart, researchers have discovered. , ... standard TENS machine like those designed to relieve labour ... small raised flap at the front of the ear ... stimulation changed the influence of the nervous system on ... drive failing hearts too hard. , Professor Jim Deuchars, ...
(Date:8/20/2014)... GraphDB™ 6.0 from ... to the enterprise replication cluster, faster loading speeds, ... and Elasticsearch. This release happens to coincide with ... – GraphDB™ was formerly known as OWLIM. ... mature enterprise resilient RDF triplestore will also benefit ...
Breaking Biology Technology:PAREXEL International To Present At Baird Healthcare Conference 2Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2'Tickling' your ear could be good for your heart 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 3Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 4
... , , , ... the Sciences in Education over the Next Decade , WASHINGTON, Dec. ... continuously published magazine in the U.S., hosted The Decade-2 ... to promote the teaching of math and science to America,s students and was ...
... , , PROVIDENCE, R.I., Dec. 9 The ... disease (AD), which was conducted at 30 sites around the ... Neurology®. Lead author, Stephen P. Salloway, MD, MS, director ... professor of neurology and psychiatry at the Warren Alpert Medical ...
... , SAN DIEGO, Dec. 9 Sangart, Inc., a ... designed to enhance the perfusion and oxygenation of ischemic ... delivery, today announced that the European Commission (EC) has ... treatment of sickle cell disease. This designation provides ten ...
Cached Biology Technology:Science Education Experts Discuss Solutions for Global Competitiveness at Scientific American Forum 2Science Education Experts Discuss Solutions for Global Competitiveness at Scientific American Forum 3Butler Hospital Neurologist Lead Author of Ground Breaking Bio-Engineered Treatment Study for Alzheimer's Disease 2Sangart, Inc. Receives European Orphan Drug Designation for the Use of MP4CO in Patients With Sickle Cell Disease 2Sangart, Inc. Receives European Orphan Drug Designation for the Use of MP4CO in Patients With Sickle Cell Disease 3
(Date:8/21/2014)... ignore, but they are the ultimate source of all ... increasingly dependent on algae, too, to suck up climate-warming ... the bottom of the ocean. Now, by using a ... evidence showing that viruses infecting those algae are driving ... all else stays essentially the same, and this has ...
(Date:8/21/2014)... the food intake, health and quality of life of ... projects at the University of Waterloo receiving close to ... Health Research (CIHR). , Professor Heather Keller, of ... a Schlegel research chair in nutrition and aging, will ... Canadians living in long-term care homes are poorly nourished. ...
(Date:8/21/2014)... is a key region in the global oceanic circulation. "On ... warm Atlantic water flows to the north into the Arctic ... and sea ice push their way out of the Arctic ... water cools here on its way to the north and ... in this manner drives the global band of oceanic currents ...
Breaking Biology News(10 mins):Viruses take down massive algal blooms, with big implications for climate 2Grants will fund landmark aging research at Waterloo 2Arctic sea ice influenced force of the Gulf Stream 2Arctic sea ice influenced force of the Gulf Stream 3
... cause poor lung development in children, making them more vulnerable ... in life, say researchers at the University of Pittsburgh Graduate ... Environmental Health. Their study, published online in Physiological Genomics ... in both mouse lungs and children ages 9 to 11. ...
... with the flu virus, we have investigated how the ... of the Experimental Mouse Genetics research group. In infection ... immune response is responsible for the fatal outcome of ... The findings have now been published in the scientific ...
... 2009 A material developed at the Hebrew University ... tissue) following surgery has led to approval by the ... for use in pediatric cardiac surgery patients. ... invention of novel, tailor-made, biodegradable polymers for the prevention ...
Cached Biology News:Changes in gene may stunt lung development in children 2The host makes all the difference 2Hebrew University professor's work leads to FDA approval for product 2
QPRT Immunogen: QPRT (NP_055113, 198 a.a. ~ 298 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Antibody Diluent for IHC 125 ml...
Quinolinate phosphoribosyltransferase...
JMJD2B Antibody...
Biology Products: